BVX — Bivictrix Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- £6.19m
- £4.70m
Annual balance sheet for Bivictrix Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.862 | 6.06 | 3.29 | 3.28 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.143 | 0.26 | 0.565 | 0.454 |
| Prepaid Expenses | ||||
| Total Current Assets | 1 | 6.54 | 3.96 | 3.82 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.063 | 0.339 | 0.571 | 0.476 |
| Total Assets | 1.07 | 6.88 | 4.54 | 4.29 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Current Liabilities | 0.33 | 0.379 | 0.391 | 0.624 |
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 1 | 0.554 | 0.579 | 0.758 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 0.067 | 6.33 | 3.96 | 3.54 |
| Total Liabilities & Shareholders' Equity | 1.07 | 6.88 | 4.54 | 4.29 |
| Total Common Shares Outstanding |